Apellis Pharmaceuticals, Inc. (APLS)
24.68
+0.90
(+3.78%)
USD |
NASDAQ |
Dec 10, 16:00
24.68
0.00 (0.00%)
After-Hours: 20:00
Apellis Pharmaceuticals EPS Diluted (Quarterly): 1.658 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Biogen, Inc. | 3.171 |
| Amicus Therapeutics, Inc. | 0.0558 |
| Fortress Biotech, Inc. | 0.111 |
| Ultragenyx Pharmaceutical, Inc. | -1.808 |
| Fulcrum Therapeutics, Inc. | -0.313 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 215.72M |
| Revenue (Quarterly) | 458.58M |
| Total Expenses (Quarterly) | 242.86M |
| Enterprise Value | 3.117B |
| Gross Profit Margin (Quarterly) | 94.58% |
| Profit Margin (Quarterly) | 47.04% |
| Earnings Yield | 1.20% |
| Operating Earnings Yield | 2.58% |
| Normalized Earnings Yield | 1.203 |